Lascco
Company Team Projects Media Contact
 
  COMBIOXIN Sepstone


COMBIOXIN (www.combioxin.com)

An innovative therapeutic approach to bacterial infection

COMBIOXIN SA develops innovative anti-virulence treatments for serious bacterial infections, including those caused by antibiotic-resistant strains. The lead candidate, CAL02, is a first-in-class, clinical-stage non-antibiotic liposomal drug that neutralizes bacterial toxins, protects against infection severity and complications, and improves antibiotic efficacy.

CAL02 is currently being tested in a randomised, multicentre, multinational, double-blind, placebo-controlled, Phase I/IIa study aiming at assessing the safety, tolerability, and efficacy of CAL02 as adjunctive therapy to standard of care in ICU patients with severe pneumonia caused by Streptococcus pneumoniae.

The drug effectively neutralizes virulence factors produced by Staphylococcus aureus, Streptococcus pneumoniae, Pseudomonas aeruginosa and various other streptococcal or clostridium strains. It is therefore active against the most frequent bacteria - including antibiotic-resistant pathogens (e.g. MRSA) - that cause severe infections such as community- and hospital-acquired pneumonia, ventilator-associated pneumonia, other nosocomial infections and meningitis.

Furthermore, CAL02 does not display any direct bactericidal activity and therefore does not impose any selective pressure on bacterial growth, conferring the key advantage of steering clear of the emergence of bacterial resistance.

For more infomation, please visit http://www.combioxin.com

 

Lascco